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The recommended use of doxycycline (DC) to broiler chicken is 100 mg/L 
via the drinking water and a 7-day withdrawal time (WDT). However, study of a 
higher dosage is desirable because of the possible increase of antimicrobial resis-
tance and disease spectrum. Tissue DC residues exceeding the current maximum 
residue levels (MRL) was our major concern. Therefore, serum concentration and 
tissue depletion of DC hyclate after administration of 200 mg/L of DC in the 
drinking water for five consecutive days were studied. The steady-state DC con-
centration (8.3 ± 0.9 μg/mL) was reached on the third day of medication. The 
elimination constant (0.05 ± 0.01 1/h), half-life (14.9 ± 1.4 h), area under concen-
tration versus time curve (81.0 ± 9.9 h·μg/mL) and mean residence time (22.7 ± 
2.5 h) were obtained using a non-compartmental pharmacokinetic model. It was 
determined that the current 7-day WDT regulation was still legitimate for the kid-
ney and liver as well as for the breast and leg muscles, which were estimated by 
linear regression analysis of the 99% upper distribution limit. The unregulated 
heart and gizzard were considered safe even when the lowest MRL of muscle 
(100 ng/g) was applied. While at the present time the extra-label use of drugs is 
only allowed under specific conditions, in the future it may become necessary to 
increase the general dosage of DC, and the current results suggest a safe range of 
DC hyclate in chicken; however, skin/fat tissue residues warrant further studies.  
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Doxycycline (DC) hyclate is a semi-synthetic, second-generation tetracy-
cline antibiotic that exerts its antimicrobial activity mainly by binding to the 30S 
ribosomal subunit of bacteria to interfere with protein synthesis (Papich and 
Riviere, 2013; Nguyen et al., 2014). DC is 5 to 10 times more lipophilic, result-
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ing in higher bioavailability and tissue penetration, larger volume of distribution, 
and longer elimination period (Papich and Riviere, 2013). DC is primarily ex-
creted into the faeces via non-biliary routes; hence, it is less toxic to patient with 
hepatic and renal insufficiency (Andrade and Tulkens, 2011; Plumb, 2015). 
Despite the wide use in human medicine, DC has been contraindicated in 
pregnancy and in young animals due to its potential for disrupting bone and tooth 
development, and thus the food safety concern remains. In veterinary medicine, 
DC has been approved for use in broiler chickens via the drinking water (100 mg/L 
or 20 mg/kg body weight) for 5 consecutive days, and a 7-day withdrawal time 
(WDT) is instigated. However, in the future it may become necessary to increase 
its dosage in poultry because of increasing antimicrobial resistance and disease 
spectra. Till now, in broiler chicken the pharmacokinetic information has been 
limited and mainly based on single daily dosing instead of continuous admini-
stration via the drinking water as practised under farm conditions. 
The maximal residue limits (MRL) established by European Union for 
doxycycline in poultry are 100 ng/g for muscle, 300 ng/g for liver and skin, and 
600 ng/g for kidney. Earlier residue data on broilers with oral medication of 
20 mg/kg body weight (BW) daily for 4–5 days indicated that the DC levels in 
muscle, liver and kidney on the 5th day after the final medication were all below 
their MRLs (Anadón et al., 1994; El-Gendi et al., 2010). Recently, one report of 
DC given at a lower dose (10 mg/kg) for 5 consecutive days indicated that the DC 
residue on the 7th day after drug withdrawal was also safe (Gajda et al., 2014). 
Nevertheless, tissue residue levels in possible extra-label use (double concentra-
tion) have not been investigated. It is questionable whether or not the current 
WDT are appropriate under field conditions. In addition, the depletion of DC 
from the gizzard and heart was unknown, although these organs are popular edi-
ble parts in eastern countries; as a result, no reference WDT was available. The 
present study was the first pharmacokinetic assessment of DC hyclate in chicken 
medicated via the drinking water in line with the field practice. 
 
 
Materials and methods 
Chemicals and reagents 
Doxycycline (as hyclate) powder was supplied by BIOVET (HydroDoxx® 
500 mg/g, Bulgaria). Analytical grade DC hyclate standard for high-performance 
liquid chromatography (HPLC) was purchased from Sigma Aldrich (St. Louis, 
MO, USA), and the solid phase extraction (SPE) cartridges (COOH, 500 mg in 
3 mL syringe tube) were purchased from J. T. Baker (Center Valley, PA, USA). 
The acetonitrile (ACN), ethyl acetate (EA), methanol (MeOH) (Echo Chemical, 
Toufen, Taiwan), hydrochloric acid, sodium hydroxide, phosphoric acid (Union 
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Chemical Works, Hsinchu, Taiwan), oxalic acid, and trichloroacetic acid (Pan-
reac Applichem, Castellar del Vallés, Spain) were all analytical grade. 
Animals 
Thirty clinically healthy, 1-day-old conventional broiler chickens were raised 
in-house until the 16th day, at which time their average body weight reached 732 ± 
72 g. The chickens were housed indoors under hygienic conditions and fed diets 
free of anticoccidials and antibiotics. The experimental protocols involving live 
animals were approved by the Institutional Animal Care and Use Committee of 
National Chung Hsing University, Taichung, Taiwan. 
Drug administration and sample collection 
Two hundred mg/L of DC in drinking water was administered ad libitum 
to the chickens for five consecutive days. The daily intake of dose was estimated 
to be approximately 35–40 mg/kg (body weight) by calculating the total amount 
of medicated water ingested. The recorded daily intake of water volume was 
consistent for each cage (1500–1700 mL) and averaged 150–170 mL/day per 
chicken. For the serum pharmacokinetic study, 1.5-mL blood samples were col-
lected from the wing veins. Three broilers each were sampled at 6, 12, 24, 48, 
72, 96 and 120 h during the 5-day medication period and 6 broilers were sampled 
at 0, 1, 2, 4, 6, 8, 12, 18 and 24 h in the first 24-hour withdrawal period. Blood 
samples were settled for 2 h at 4 °C and centrifuged at 1,400 g for 10 min for se-
rum collection. For the tissue depletion study, five broilers each were sacrificed 
with electrocution at the 3rd, 5th and 7th day after the last dose, and the heart, 
gizzard, breast muscle, leg muscle, liver and kidney were collected. 
Sample preparation and drug analysis 
Sample preparations and the HPLC method for DC determination were 
modified from previous reports (Gastearena et al., 1993; Gajda et al., 2008) and 
validated for this study. Briefly, for serum samples, 0.5 mL serum was mixed 
with 0.5 mL of phosphoric acid buffer (0.2 M, pH 6) before 3 mL of ethyl ace-
tate (EA) was added, and vortexed for 5 min. The mixtures were centrifuged at 
1,700 g for 10 min and 2.5-mL supernatants were collected and evaporated to 
dryness in a chemical hood under gentle nitrogen stream. The sample was then 
reconstituted with 0.2 mL of mobile phase for HPLC analysis. For tissue samples, 
5 g of minced tissue was vortexed in 3 mL of oxalic acid buffer (0.02 M, pH 4) 
for 30 sec. The mixture was extracted with 15 mL of EA and 0.5 mL of 10% tri-
chloroacetic acid. This liquid–liquid extraction was repeated twice with EA 
alone, and the total supernatants were pooled for SPE. The SPE cartridge was 
first conditioned with 5 mL of EA before loading the supernatant. After washing 
with 2 mL of EA, the analyte was eluted with 2 mL of mobile phase, and 50 μL 
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was used for HPLC analysis. The HPLC system consisted of a pump (1525 bi-
nary pump, Waters), an injector (model 7725i, Rheodyne), and an ultraviolet de-
tector (2489 UV/Visible, Waters). A reverse-phase column (Luna® C8, 5 μm par-
ticle size, 250 × 4.6 mm, Phenomenex) was used for chromatographic separation 
at ambient temperature with a mobile phase consisting of 20 mM oxalic acid–
ACN–MeOH (65:20:15) set at a flow rate of 1 mL/min. Ultraviolet detection was 
performed at 355 nm. The recoveries at levels equivalent to 0.5, 1 and 1.5 MRLs 
for respective tissues were evaluated and the limits of detection and quantifica-
tion were 5 ng/g and 16 ng/g, respectively. 
Pharmacokinetics 
Serum pharmacokinetic parameters were analysed using commercially 
available software (WinNonlin® version 1.1, Pharsight) utilizing non-compart-
mental analysis. The area under the concentration–time curve (AUC), the area 
under the first moment curve (AUMC), the elimination constant (Ke), the elimi-
nation half-life (T1/2) and the mean residence time (MRT) were obtained accord-
ingly. The DC concentrations, AUC, AUMC, Ke, T1/2 and MRT were shown as 
mean ± SEM. Clearance (CL) and steady-state volume of distribution (Vss) can be 
calculated using the following formula: CL = Dose/AUC, and Vss = MRT × CL. 
 
 
Results 
Pharmacokinetic study 
The serum DC concentration rose to 4.4 ± 0.4 μg/mL at the 6th h after the 
first medication and reached a steady-state concentration of 8.3 ± 0.9 μg/mL at 
72 h (Fig. 1a). After the last dose, the DC level declined to half of the steady-state 
concentration after 6 h. The average serum concentration at the 24th h was around 
2.0 ± 0.3 μg/mL (Fig. 1b). The concentration–time curve during the first 24-h 
elimination was best described by a non-compartmental pharmacokinetic model, of 
which the variables were listed and compared to previous studies (Table 1). 
Tissue residues 
On the 3rd day, in decreasing order, the DC concentration was the highest 
in the heart, followed by the gizzard, kidneys, liver, leg muscle and breast muscle. 
The heart and the breast muscle contained 252 ± 93 ng/g and 62 ± 16 ng/g of DC, 
respectively. On the 5th day, the tissue DC concentrations all decreased below 
their respective MRLs (Fig. 2). A differential depletion rate of tissue residues 
during the first 7 days was also noted (Table 2). The drug concentration fell more 
precipitately on days 5–7 than on days 3–5 for breast muscle, liver and kidney. 
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Fig. 1. Mean serum doxycycline (DC) concentration during (a) 5-day medication period at 
40 mg/kg BW via drinking water, and (b) the first 24 hours after the last dosage administered 
(mean ± SEM, n = 6) 
Table 1 
Pharmacokinetic parameters of doxycycline (DC) after medication via the drinking water for 
5 days (comparison was made to previous studies after single oral dose) 
Variables Present study Soliman et al.  (2015) 
El-Gendi et al. 
(2010) 
Hantash et al.  
(2008) 
Breed Cobb – Hubbard – 
Drug salt hyclate HCl HCl HCl 
Route Drinking water Intra-crop Intra-crop Intra-crop 
Dose 40 20 20 20 
Duration 5 days Single dose Single dose Single dose 
Cmax (μg/mL) – 4.7 ± 0.6 4.5 ± 0.2 5.4 ± 0.3 
Css (μg/mL) 8.3 ± 0.9 – – – 
Ke (h–1) 0.05 ± 0.01 0.05 ± 0.002 0.12 ± 0.01 0.04 ± 0.01 
T1/2 (h) 14.9 ± 1.4 13.9 ± 0.4 5.7 ± 0.3 13.9 ± 0.8 
MRT (h) 22.7 ± 2.5 – – 9.4 ± 0.2 
AUC (μg · h/mL) 126.8 ± 13.8 21.7 ± 1.48 39.8 ± 4.3 89.4 ± 3.0 
AUMC (μg · h2/mL) 2975.4 ± 484.7 – – 836.7 ± 19.7 
 
 
For the estimation of WDT in these tissues, 99% upper distribution limits 
of the 3rd, 5th and 7th days were used to establish the regression line. The time 
at which the regression lines intercepted with the MRL was the estimated WDT. 
The results suggested that the kidney, the liver and the two muscles all fell 
within the current WDT regulation of 7 days (Fig. 3). The gizzard and the heart 
were also evaluated using the current MRLs established for kidney, liver and 
muscle (Fig. 4).  
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Fig. 2. Depletion profile of doxycycline (DC) in various tissues (mean ± SEM, n = 5) 
Table 2 
Comparison on the rate of doxycycline (DC) depletion (by percentage decrease) between two  
sampling time points 
Tissue Gizzard % Heart % Breast % Leg % Liver % Kidney % 
Days 3–5 60 69 38 35 49 9 
Days 5–7 60 35 51 17 81 68 
 
 
Discussion 
Doxycycline has been used for the treatment of avian respiratory infec-
tious diseases such as chlamydiosis, mycoplasmosis and other aerobic/anaerobic 
bacterial infections, but its serum pharmacokinetic data under double-concentra-
tion use and field conditions were unavailable in previous studies. In the present 
study, the Css (8.3 ± 0.9 μg/mL) was above most inhibitory concentrations required 
for DC to exert a bacteriostatic effect against Staphylococcus aureus (4.8 μg/mL), 
Streptococcus pneumoniae (1.6 μg/mL), Pasteurella multocida (1.6 μg/mL), and 
Escherichia coli (8 μg/mL) (Cunha et al., 2000). This Css was also 42 times higher 
than the MIC90 for Mycoplasma gallisepticum (0.125 μg/mL) (Burch and Valks, 
2002). After drug withdrawal, the concentration–time curve during the first 24-h 
elimination was compared to previous studies (Hantash et al., 2008; Soliman et 
al., 2015) (Table 1). While most parameters showed an expected increase likely 
associated with the increased dosages, the T1/2 was mostly comparable to pub-
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lished reports despite differences in the dosing regimen. The results may suggest 
the proper capacity of chicken to eliminate DC under current extra-label drug use 
(ELDU) conditions. 
 
Fig. 3. Estimation of withdrawal time (WDT) on muscles, liver, and kidney by linear regression of 
the 99% upper distribution limits (mean ± SEM, n = 5) 
 
At the usual recommended dose (20 mg/kg BW) of DC, the residues should 
fall below their MRLs in the respective tissues within the regulated 7 days (the 
WDT). The present investigation revealed that even at nearly double dosage (35–
40 mg/kg BW), the residues in kidney, liver and muscles all decreased below 
their respective MRLs already 5 days after drug withdrawal, in the same way as 
in the case of the 20 mg/kg BW dosage regimen (Anadón et al., 1994; El-Gendi 
et al., 2010). Probably, the current regulation actually allows certain degrees of 
safe caution. So far, MRLs have been established in four major edible tissues in-
cluding kidney (600 ng/g), liver and skin (300 ng/g), and muscle (100 ng/g). The 
heart and gizzard, although being popular food items in many regions of the 
world, did not have recommended MRLs which could be used for estimating a 
proper WDT. Traditionally, WDT was established either by a non-parametric 
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approach or by linear regression. The non-parametric approach has the disadvan-
tage of no assumption from the obtained population data (Vranic et al., 2003) 
and the ethical concern of increased experimental animal number. On the other 
hand, the linear regression method depicting 99% upper distribution limit was 
recommended by the Food and Drug Administration (Damte et al., 2012). With 
this method, the estimated WDT for gizzard and heart were both within 7 days 
based on the lowest MRL for muscle (100 ng/g) (Fig. 4). Therefore, while there 
were no recommended MRLs for these two tissues, our data suggested that the 
current 7-day WDT was likely enough to avoid residue infringement. In fact, the 
MRL determination for an organ/tissue also considers the theoretical standard food 
basket (consisting of 300 g muscle, 100 g liver, 50 g kidney, 50 g fat, 1500 g milk, 
100 g eggs and 20 g honey) (WHO, 2009), which may differ in various cultures 
and countries. Since the gizzard and the heart were often considered as viscera in 
eastern cultures, their MRLs could be tentatively estimated based on the MRL of 
liver (300 ng/g). Under this assumption, a 5-day WDT for both heart and gizzard 
could be determined (Fig. 4). Extended from the food basket concept, the knowl-
edge of total tissue residues also carries important implications regarding food 
safety. For instance, the chicken essence, which is the brewed juice of a whole 
gutted chicken body, might contain non-negligible amounts of DC if the WDT is 
not strictly followed. Estimation based on the current data indicated that an ali-
quot of chicken essence may contain at least 21 μg of DC residues (assuming a 
1.2-kg chicken, 60% of which is muscle), which represents 12% of the accept-
able daily intake (ADI) for this drug in a 60-kg person. The number could in-
crease to 32–64% of ADI if the skin were also included in the preparation of 
chicken essence (assuming the skin representing 10% of the gutted torso and DC 
at MRL level). The current study provides reliable information for risk assess-
ment of this drug under various food-basket assumptions because it is conducted 
in line with the manner the drug is administered in the field. 
Some minor observations in this study are worth mentioning. The rank or-
der of residue levels was the same as in previous studies using doxycycline HCl 
at 20 mg/kg BW (Anadón et al., 1994; El-Gendi et al., 2010), suggesting that the 
distribution and elimination behaviour of these two common DC salts might be 
similar. In this study, the breast and leg muscles were separately studied and 
found to exhibit one-day difference in WDT (4 days vs. 5 days). Differential dis-
tribution and elimination of antibiotics between these two muscle sites has been 
reported previously in pigeon (Yeh et al., 2008). A potential explanation might 
be the difference between the two sites in local blood flow, local capillary den-
sity and capillary permeability. While the basis for the differences between the 
two muscle sites is unknown, our results highlighted the fact that even very simi-
lar tissues might have different residual times. In addition, it is interesting to note 
that the DC concentration in the breast muscle, liver and kidney decreased more 
precipitately (by percentile) between days 5–7 than between days 3–5, while in 
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the heart and leg muscle the DC concentration decreased more rapidly between 
days 3–5, indicating the differential rate of DC elimination by tissues. This dif-
ference was especially evident for the kidney (9% vs. 68%). The reasons for the 
time-dependent differences in elimination and its influence on the WDT remain to 
be elucidated, but based on the fact that this phenomenon was also observed when 
DC was co-administered with the anticoccidial diclazuril in the feed (1 mg/kg) 
(El-Gendi et al., 2010), it is plausible that the relatively high plasma protein 
binding (80–90%) (Papich and Riviere, 2013) and the varying degrees of tissue 
bindings of DC contributed to this observation. 
 
Fig. 4. Estimation of withdrawal time (WDT) on gizzard and heart based on various maximum 
residue levels (MRLs; mean ± SEM, n = 5) 
 
In conclusion, the pharmacokinetic behaviour of DC administered at 
40 mg/kg dosage level (200 mg/L water) was for the most part similar to that ob-
served with the single dose (20 mg/kg) widely used in previous studies. All tis-
sue residues were below their respective MRLs at times shorter than the regu-
lated WDT. In addition to the common edible tissues (kidney, liver and muscles), 
the heart and the gizzard were also considered safe under the 7-day WDT regula-
tion based on the most strict provisional MRL used for muscle. The current study 
also demonstrated a differential rate of DC depletion in the first and second half 
of the 7-day withdrawal period and documented differences in residual levels be-
tween breast and leg muscles. Although these results pointed to the conclusion that 
the current 7-day WDT might still be appropriate at the doubled dosage (40 mg/kg) 
level, it must be emphasised that our data are initial assessments, ELDU is not 
advisable, and the residue levels in skin/fat warrant further investigation. 
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